Additionally, anti-melanoma cell adhesion molecule (MCAM) CAR-NK cells have shown significant antitumor activity in osteosarcoma models, suggesting that targeting MCAM could be a viable strategy for OS immunotherapy (74). Here, MCAM is linked to osteosarcoma.